DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Analysts

DBV Technologies S.A. (NASDAQ:DBVT) has earned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $38.65.

DBVT has been the topic of a number of research reports. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research note on Wednesday, December 17th. Guggenheim restated a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research report on Friday, March 27th. Citizens Jmp increased their price target on DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a report on Friday, March 27th. HC Wainwright set a $40.00 price objective on DBV Technologies in a research report on Thursday, December 18th. Finally, Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $21.06 on Friday. The firm has a 50-day simple moving average of $21.42 and a 200-day simple moving average of $17.66. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -4.03 and a beta of -0.94. DBV Technologies has a 52 week low of $6.00 and a 52 week high of $26.18.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The business had revenue of $0.65 million for the quarter. As a group, equities research analysts expect that DBV Technologies will post -7.05 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Artisan Partners Limited Partnership grew its holdings in shares of DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the period. Siren L.L.C. purchased a new position in DBV Technologies during the fourth quarter worth about $35,606,000. Vivo Capital LLC boosted its holdings in DBV Technologies by 133.4% in the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after purchasing an additional 1,407,120 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at approximately $9,649,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.